Breast Cancer

In younger patients with ductal carcinoma in situ (DCIS), boost irradiation reduced local recurrences by at least half when added to standard radiotherapy, Gunther Gruber, MD

The investigational agent lapatinib (Tykerb) when added to paclitaxel has significant clinical activity as neoadjuvant treatment of HER2-positive inflammatory breast cancer (IBC)

This month, we offer an example of persistence by the patient and her family resulting in a reversal of coverage denial.

In the clinical practice setting, almost a quarter of women treated for breast cancer stop tamoxifen within 1 year, a rate twice as high as indicated by previous studies.

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel, Abraxane) given weekly outperformed docetaxel (Taxotere) given every 3 weeks as first-line treatment of metastatic breast cancer.

A mind-body technique known as self-hypnotic relaxation performed during certain medical procedures significantly reduces pain, anxiety, drug use, and complications.

Reversing a decades-old trend, the incidence of invasive breast cancer dropped dramatically in 2003, relative to 2002, possibly a result of postmenopausal women discontinuing hormone replacement therapy (HRT) due to breast cancer concerns

Bisphosphonates are an important part of managing bony metastasis of prostate, breast, lung, and other cancers but can cause osteonecrosis of the jaw (ONJ) in some patients.

A random sampling of 2.3% of the imaging centers that meet Mammography Quality Standards Act (MQSA) certification showed that the national median cash price for a screening mammogram is more than double the price that is reimbursed by Medicare.

In a randomized trial, breast cancer patients who underwent postoperative intensity modulated radiation therapy (IMRT) had a markedly reduced incidence of moist desquamation and overall skin toxicity, compared with those receiving standard radiation therapy.

In its second annual "Clinical Cancer Advances" report, the American Society of Clinical Oncology (ASCO) selected six notable developments in clinical cancer research as most important in 2006.

In a new study, elasticity imaging software was highly sensitive and specific when classifying malignant and benign breast lesions

New subgroup analyses from the Digital Mammographic Imaging Screening Trial (DMIST) Investigators Group confirm previous results that digital screening mammography is significantly more accurate than film screening mammography in young women with dense breasts but not in women overall.

A second interim efficacy analysis of the phase III Breast Cancer International Research Group (BCIRG) 006 study confirmed the benefits reported previously for docetaxel (Taxotere)-plus-trastuzumab (Herceptin) regimens in early HER2-positive breast cancer, and further showed a higher rate of toxicity for anthracycline-based regimens.

The majority of invasive breast cancer patients present with hormone receptor-positive disease, and modulation of estrogen receptor (ER) activation is an essential component of systemic adjuvant therapy for these women. While tamoxifen has traditionally been the primary adjuvant endocrine therapy for all ER-positive women, recent trials evaluating the use of aromatase inhibitors (AIs) have challenged this standard in postmenopausal women, and ongoing trials are examining the optimal use of endocrine therapy in younger women. Issues regarding the optimal approach to endocrine therapy in both pre- and postmenopausal women are examined in this review.

The majority of invasive breast cancer patients present with hormone receptor-positive disease, and modulation of estrogen receptor (ER) activation is an essential component of systemic adjuvant therapy for these women. While tamoxifen has traditionally been the primary adjuvant endocrine therapy for all ER-positive women, recent trials evaluating the use of aromatase inhibitors (AIs) have challenged this standard in postmenopausal women, and ongoing trials are examining the optimal use of endocrine therapy in younger women. Issues regarding the optimal approach to endocrine therapy in both pre- and postmenopausal women are examined in this review.

A phase III study reporting that lapatinib (Tykerb) plus capecitabine (Xeloda) is superior to capecitabine alone in women with HER2-positive advanced breast cancer who had progressed following prior therapy, including trastuzumab (Herceptin)

The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) have published a clinical practice guideline on improving the accuracy of human epidermal growth factor receptor 2 (HER2) testing for breast cancer patients.

Abraxis BioScience, Inc, presented data at the 29th Annual San Antonio Breast Cancer Symposium (SABCS) from an interim analysis of a randomized, head-to-head phase II trial of albumin-bound paclitaxel (Abraxane) vs docetaxel (Taxotere), in the first-line treatment of metastatic breast cancer.

The majority of invasive breast cancer patients present with hormone receptor-positive disease, and modulation of estrogen receptor (ER) activation is an essential component of systemic adjuvant therapy for these women. While tamoxifen has traditionally been the primary adjuvant endocrine therapy for all ER-positive women, recent trials evaluating the use of aromatase inhibitors (AIs) have challenged this standard in postmenopausal women, and ongoing trials are examining the optimal use of endocrine therapy in younger women. Issues regarding the optimal approach to endocrine therapy in both pre- and postmenopausal women are examined in this review.

Grape seed extract was effective in inhibiting the enzyme aromatase in both cell culture and animal studies, according to researchers from the City of Hope, Duarte, California. A phase I prevention trial is now underway to test whether this extract lowers estrogen levels in healthy postmenopausal women, and, if so, which dose is the most effective

Two experimental drugs used together were shown to be far more effective than either alone in preventing the development of estrogen-receptor-negative (ER-) breast tumors in mice, Karen Liby, PhD, a postdoctoral fellow at Dartmouth Medical School, said at the AACR's Frontiers in Cancer Prevention Research meeting (abstract PR-08). One of the drugs, LG100268, developed by Ligand Pharmaceuticals, Inc., San Diego, California, is a rexinoid, which binds to retinoid X receptors. Known as 268, the agent has previously been reported to be effective in preventing and treating mammary tumors in animal models of ER+ breast cancer.

After 8 years' follow-up, tamoxifen plus breast radiation resulted in a lower rate of ipsilateral breast relapse than tamoxifen alone in women over 50 with early-stage, node-negative breast cancer treated initially with lumpectomy

At 48 months' follow-up, adjuvant treatment of early breast cancer with epirubicin (Ellence) plus CMF showed significantly improved relapse-free and overall survival, compared with CMF alone, according to combined results of two large randomized studies. Christopher J. Poole, MD, of the University of Birmingham, and his colleagues reported the results in the New England Journal of Medicine

Use of complementary and alternative medicine (CAM) is typically higher among cancer patients than the general population. Researchers from the Dana-Farber Cancer Institute further refined this observation by studying the use of CAM among women with varying degrees of breast cancer risk. Reporting at the Third International Conference of the Society for Integrative Oncology (abstract F075), they found that breast cancer survivors with a family history of cancer used significantly more CAM than the other groups.